Introduction {#S1}
============

The central nervous system (CNS) consists of the brain, spinal cord, and retina, which are composed of more than 100 billion individual nerve cells surrounded by bone structures ([@B106]). The CNS has long been recognized as immune-privileged, attributed to the blood brain barrier (BBB) and the lack of lymphatic vessels within the parenchyma ([@B36]). Nevertheless, the CNS is unable to generate robust adaptive immune responses ([@B114]). In the absence of immediate or long-term medical care, this situation could lead to permanent damage or death following a severe nervous system injury ([@B162]). The treatment of CNS diseases gets further complicated by the BBB, which acts as a shield for foreign substances including therapeutic molecules ([@B55]). Potential treatments against neurodegenerative disorders are considered difficult to implement because of the limited access to the CNS and the aggressiveness of surgical interventions ([@B149]).

It is now known that central axons are capable of regenerating after injury, but their success is highly dependent on their local environment ([@B53]; [@B145]). The composition of the microenvironment is defined by the presence of reactive neural cells. Astrocytes and microglia secrete biomolecules as cytokines, chemokines and growth factors in response to insults. These cells display a big heterogeneity (in morphology, function, and gene expression) and have been associated with both beneficial and detrimental regenerative outcomes on CNS injury ([@B5]; [@B62]). It is also known that the adult CNS possesses neural stem cells with the ability to differentiate into neurons and glia. However, these stem cells need a neurogenic microenvironment to achieve migration and differentiation ([@B40]). Recent advances in biomaterials have encouraged the search to overcome these challenges, either on their own or as vehicles for stem cell, genetic material, or bioactive molecule delivery ([@B39]). These biomaterials can have a natural or synthetic origin. Natural biomaterials often present good biocompatibility, biodegradability, and cell adhesion but can exhibit some disadvantages as poor mechanical properties or trigger an immune response. Their synthetic counterparts are often easier to chemically modify and have low immune responses but may contain toxic substances ([@B79]; [@B159]). Thus, natural and synthetic biomaterials are frequently used together to exploit the advantages of both, resulting in products with the desired characteristics for each application.

Currently, chitosan is one of the leading natural biomaterials for CNS applications, both in its natural form or as a modified derivative. In biomolecules delivery, it stands out for its penetration enhancement ability and mucoadhesive capacity, which make it a great material for nose-to-brain approaches ([@B116]; [@B174]). In tissue engineering and regenerative medicine, chitosan and its derivatives have shown to promote axonal regeneration, anti-inflammation, and to successfully deliver neurotrophic factors and cells with a consequently functional recovery ([@B159]). In this way, chitosan-based biomaterials have become increasingly popular to use, alone or in combination with other molecules. This review offers an overview of the physicochemical and biological properties of chitosan and its derivatives. These are useful for different applications, focusing on the delivery of therapeutic molecules and regenerative approaches in the CNS. A literature review was performed through online platforms as PubMed, ScienceDirect, and the National Library of Medicine ([clinicaltrials.gov](https://clinicaltrials.gov)), considering only the works published in the last 5 years. This review aims to show the reader the current trends and limitations of this biopolymer in biomedical applications directed toward the CNS.

Chitosan {#S2}
========

Chitosan is a polysaccharide mainly composed of D-glucosamine and, in a lower proportion, N-acetyl-D-glucosamine units randomly β-(1-4)-linked. It can be obtained by deacetylation processes of chitin, which has been recognized as the second most abundant polysaccharide in nature, after cellulose. Even though the main source of chitin is crustacean shell, recent technologies have made possible the obtention of chitin and chitosan from other sources like insects and microorganisms ([@B109]; [@B175]). Particularly, fungal sources have gained increased attention due to some potential advantages like a homogeneous polymer length, a high degree of deacetylation, and high solubility ([@B43]). In general, there are two types of processes to obtain chitosan: chemical and biological. The chemical method is the most commonly performed at an industrial scale, using strong acid and alkaline treatments ([@B35]). Biological methods involve microorganisms and enzymes ([@B7]), but despite the efforts to achieve scalable enzymatic deacetylation, the high crystallinity of chitin remains the main obstacle ([@B59]).

The source and obtention process of chitosan are important factors to consider according to the desired application. These factors define the final product characteristics. For biomedical applications, its purity, molecular weight (Mw), crystallinity, and deacetylation degree (DD) are of great importance ([@B99]). These factors deeply correlate with chitosan's mechanical and biological properties. [@B6] reported the relationship between the physicochemical properties of chitosan and its behavior in biomedical applications. This will be further detailed for each biomedical application described in this work.

The increasing interest in chitosan as a biomaterial is due to its natural origin and several biological properties: biocompatibility, non-toxicity, non-allergenicity, and biodegradability, as well as its antifungal, antibacterial, antioxidant, anti-tumor and anti-inflammatory activities. Besides, it has been recognized as an immunoadjuvant, anti-thrombogenic and anti-cholesteremic agent ([@B171]; [@B65]). It also possesses high versatility, so it can be used in many physical forms as fibers (and nano-fibers), gels, sponges, beads, films, particles (and nanoparticles), membranes and scaffolds ([@B34]; [@B118]). All these properties make chitosan adequate for many biomedical applications as drug delivery, gene delivery, tissue engineering, and regenerative therapies, among others. However, when it is used on its own, it has poor mechanical properties in wet conditions and low solubility at pH \> 7.0. This situation has led to the search of different strategies to overcome chitosan deficiencies by its combination with other materials or through changes in its superficial structure.

It is important to highlight that chitosan is a polycationic polymer, this attribute is conferred by the protonation of D-glucosamine which forms a positively charged moiety (NH~3~^+^) at neutral/physiological pH ([@B93]). Despite the versatility that this characteristic gives to chitosan, cationic polymers have been reported as neurotoxic and CNS damage inducers ([@B77]). The neurotoxicity has been associated with chitosan's particle size through inflammasome activation ([@B18]). However, the evaluation of chitosan's neurotoxicity is still limited and not detailed. On the other hand, chitosan and its derivatives have also been reported as neuroprotective over different neuronal disorders including Alzheimer's and Parkinson's disease, sclerosis, stroke, and injury, among others ([@B102]; [@B50]; [@B101]).

Chitosan Derivatives {#S3}
====================

The molecular structure of chitosan's units contains an amino/acetamido group at C-2, a secondary hydroxyl group at C-3 and a primary hydroxyl group at C-6 ([Figure 1A](#F1){ref-type="fig"}). So, the improving modifications that have been developed for this polymer make use of these groups by grafting other molecules. Some of these modifications consist of carboxyalkylation, thiolation, sulfation, phosphorylation, esterification, graft copolymerization, and cross-linking strategies ([@B92]; [@B94]). These modifications confer new and unique properties to the obtained products. For example, chitosan has been grafted with heparin to increase its anticoagulant and angiogenic properties, and to increase its affinity for growth factors ([@B136]). It has also been grafted with laminin-derived peptides to facilitate the attachment of neurons and neurite outgrowth ([@B69]). Many molecules can be grafted to improve the application of chitosan to the CNS but have not been evaluated yet. Dicarboxylic acids contain two binding sites that can lead to the crosslinking of chitosan polymeric chains and offer an antioxidant environment. In the same way, hydroxycinnamic acids possesses an important antioxidant activity. For example, the release of ferulic acid into the lesion site of traumatic brain injury (TBI) has shown to effectively protect further secondary injury through the inhibition of neurological oxidative stress ([@B29]). Nevertheless, these acids have mainly been grafted to chitosan to modify its physicochemical characteristics as solubility, thermal stability, or rheological properties, and have not been widely studied into the CNS ([@B80]).

![Molecular structure of chitosan **(A)** and some of its derivatives: N-carboxymethyl chitosan **(B)**, N-trimethyl chitosan **(C)**, and thiolated chitosan **(D)**.](fbioe-08-00389-g001){#F1}

Among the most commonly used modifications of chitosan for biomedical applications directed to CNS are carboxymethylation, N-trimethylation, and thiolation ([Figures 1B--D](#F1){ref-type="fig"}, respectively). These modifications confer new properties to chitosan, as solubility and mucoadhesiveness, converting these biomaterials into proper substrates for biomolecule delivery. Chitosan graft copolymerization is also widely used for CNS application, because it allows to obtain polymers with controlled structures and activities. These are defined by the graft characteristics, including the structure of the molecule, its length, and number (or binding degree). Copolymerization is widely used for the elaboration of tailor-made scaffolds ([@B92]). In addition to the graft attributes, the binding site also plays an important role in the final properties of chitosan-based biomaterials. [@B27] produced 6-O-sulfated chitosan and observed a strong effect of the sulfate site in promoting the neural differentiation of mouse embryonic stem cells.

Carboxymethyl Chitosan (CMC) {#S3.SS1}
----------------------------

The introduction of carboxyalkyl groups into the structure of chitosan, as carboxymethyl, has been developed mainly as a strategy for increasing chitosan's solubility. The reaction occurs either at the C6 hydroxyl group or at the NH~2~ moiety, giving N-CMC, O-CMC or N,O-CMC as products. These derivatives are amphoteric polymers that produce water-soluble compounds with pH-dependent solubility, water retention properties, biodegradability, biocompatibility, and antioxidant activity ([@B94]; [@B130]; [@B163]). Therefore, these amphoteric polymers can be loaded with hydrophobic drugs and display strong bioactivity ([@B152]). Moreover, the presence of the functional --OH, --NH~2~, and --COOH groups in its structure gives the possibility of being easily modified. For example, CMC has been crosslinked with alginate and agarose to be used as a scaffold for stem cell *in situ* differentiation into functional neurons and supporting neuroglia ([@B47]). CMC has also been employed to enhance the efficacy of active constituents with poor solubility and bioavailability, and increase brain drug concentration ([@B28]; [@B81]). However, Wahba and collaborators developed a galantamine delivery system, against Alzheimer's disease, attaching galantamine to ceria-containing hydroxyapatite as well as ceria-containing CMC-coated hydroxyapatite nanocomposites. They found that the CMC coating delayed the *in vitro* release for galantamine and nanoceria ([@B156]).

N-Trimethyl Chitosan (TMC) {#S3.SS2}
--------------------------

Methylation consists in the introduction of various alkyl groups at the amino groups of chitosan. The most common product of these reactions is TMC, which is considered one of the strongest mucoadhesive polymers due to its cationic nature ([@B82]). That is why it has been used for brain-targeting drug delivery, showing great potential in nose-to-brain applications ([@B67]; [@B88]; [@B103]). Another promising application of TMC is its use to treat brain tumors. For example, Turabee and his team found that the addition of TMC to a pluronic F127 hydrogel increased the biological activity of docetaxel against U87-MG cells. The pluronic F127-TMC/docetaxel hydrogel was evaluated *in vivo* employing BALB/c nude mice and showed sustained release of docetaxel with tumor suppression ([@B148]). Similarly, [@B127] observed a significant improvement in cytotoxicity of Piperine-loaded TMC nanoparticles on human brain cancer cell line Hs683.

Thiolated Chitosan {#S3.SS3}
------------------

Thiolation is the reaction of primary amino groups of chitosan with coupling reagents that contain thiol groups (thioglycolic acid, 2-iminothiolane, cysteine, and thiobutylamidine). This product has high permeation, mucoadhesion, higher solubility at physiological pH and displays *in situ* gelling properties ([@B137]). These properties present thiolated chitosan as a good substrate for drug delivery to the brain, mainly used as nanoparticles ([@B105], [@B104]; [@B133]; [@B142]). In this way, [@B104] studied brain uptake of cyclobenzaprine HCl-loaded thiolated chitosan nanoparticles on Swiss albino mice after intranasal administration and observed that thiolation of chitosan reduced trans-mucosal toxicity and enhanced the bioavailability. The *in situ* gelling ability makes thiolated chitosan suitable not only for nose-to-brain applications but also for the elaboration of scaffolds. However, it has not been widely used for neural tissue engineering. For this purpose, methacrylamide chitosan has been thiolated, giving as products porous and biodegradable scaffolds that are suitable for cell growth and neural stem cell differentiation in 3D ([@B173]; [@B73]).

Grafting Copolymerization of Chitosan {#S3.SS4}
-------------------------------------

Frequently, chitosan is grafted with other polymers to reach copolymerization. The graft polymer is selected by its chemical, mechanical or biological properties and the copolymerization results in a chitosan-based product with added characteristics. For example, polyethylene glycol (PEG)-grafted chitosan derivatives have increased solubility over a wide range of pH and have shown enhanced mucoadhesion ([@B12]). In this way, 2-O-PEGylated chitosan has been used for the elaboration of siRNA-carrying nanoparticles that target the brain to treat neurodegenerative diseases ([@B83]). Other polymers that have been grafted to chitosan for CNS application are gelatin ([@B41]), poly lactic-co-glycolic acid (PLGA) ([@B146]), poly (3,4 ethylenedioxythiophene) (PEDOT) ([@B157]), alginate, and agarose ([@B47]), among others.

Chitosan-Based Delivery Systems to CNS {#S4}
======================================

For many years, the increasing incidence of neurodegenerative disorders and the lack of functional treatments have encouraged the search for new therapeutic approaches to counteract CNS diseases. The administration routes directed to the CNS mainly consist of systemic administration, nose-to-brain, and direct injection into the brain parenchyma or cerebrospinal fluid. However, it remains challenging to find effective treatments. One of the main reasons for this is the BBB, which separates the brain from the blood supply and distinguishes between the molecules that can and cannot cross through itself. The BBB allows the entry of nutrients and hormones but restricts other external materials. Therefore, most of the therapeutic molecules are unable to cross and access to the CNS from the bloodstream, following systemic administration ([@B19]). This situation has led to the development of different strategies for aiding therapeutic molecules to permeate the BBB and to get access to the brain. Dong elaborated a review article providing an overview of the current strategies to enhance drug delivery to the brain ([@B30]). According to it, permeability enhancers, active transporters, viral vectors, nanoparticles, and exosomes have been proposed for aiding therapeutic molecules to cross the BBB after systemic administration ([@B23]; [@B30]; [@B52]). For direct administration into the brain parenchyma or cerebrospinal fluid, implantable devices have emerged as effective delivery systems that avoid systemic concerns ([@B139]). However, most of these strategies have the disadvantage of bearing low drug concentrations or being invasive. Therefore, the use of carriers/vehicles and non-conventional administration routes have emerged as a new approach for facilitating the delivery of therapeutic molecules to the brain ([@B151]; [@B15]). In this way, nose-to-brain administration has also made use of viral vectors, exosomes, and nanoparticles to achieve less invasive and more effective treatments ([@B57]; [@B10]; [@B30]; [@B75]). This information is summarized in [Figure 2](#F2){ref-type="fig"}. Nevertheless, the use of biocompatible carriers is encouraged to prevent unwanted effects and achieve high and sustained local drug delivery ([@B22]).

![Advantages and disadvantages of the current strategies to enhance therapeutic molecules delivery to the CNS.](fbioe-08-00389-g002){#F2}

Drug Delivery to CNS {#S4.SS1}
--------------------

Chitosan possesses a lot of advantages as a brain-targeted drug carrier. Coupled with its capability to penetrate the BBB, it also can control release, adhere to mucus, and open tight junctions of the nasal membrane. These abilities favor its application in nose-to-brain drug delivery strategies ([@B90]; [@B174]).

Another advantage of chitosan is its versatility, it can be used for drug delivery purposes as microspheres, capsules, hydrogels, conjugates, nanoparticles, films, beads, or tablets ([@B3]). However, nanoparticles have gained special attention in this field due to their capability to protect drugs from degradation during administration ([@B150]). Chitosan nanoparticles have shown to enhance the brain targeting efficiency and, therefore, to improve the therapeutic potential of drugs ([@B87]; [@B96]). Chitosan has also been used as a nanoparticle coating, to grant drug-loaded nanoparticles with a net positive charge and facilitate cellular internalization ([@B155]).

For drug delivery, it has been reported that the use of low Mw chitosan increases the encapsulation efficiency ([@B168]), reduces cytotoxicity and increases the degradation rate of nanoparticles, properties that have been also associated with higher DDs ([@B125]). On the other hand, the penetration in the mucin layer and the mucoadhesion strength of chitosan increase when the Mw is higher ([@B116]). It is worth mentioning that these properties are influenced when chitosan is functionalized, and they depend on the added molecules. For example, Kuo and collaborators, recently developed chitosan-PLGA nanoparticles grafted with anti-aldehyde dehydrogenase and sialic acid for brain tumor-targeted delivery of curcumin ([@B70]). They promoted the BBB permeation through N-acetylglucosamine. However, the targeting of the delivery system was improved with the addition of sialic acid and the anti-aldehyde dehydrogenase by directing it to the membrane of glioblastoma cells and brain cancer stem cells.

The use of chitosan and its derivatives for drug delivery to the brain has been employed for developing treatments against many neurological disorders, mainly for Parkinson's and Alzheimer's diseases. Other studies have been guided to treat conditions like depression, schizophrenia, migraine, brain tumor, general anxiety disorder, epilepsy, pain, viral and bacterial infections, and so on ([Table 1](#T1){ref-type="table"}). However, at the time of writing this article, only one of these studies has been taken to clinical trials ([@B122]). In that clinical research, a nasal ketamine spray with chitosan was evaluated in comparison with oral morphine to treat pain in cancer outpatients but no results have been reported yet.

###### 

Chitosan drug delivery systems for brain targeting reported in the last 5 years.

  Drug                             Presentation                                                     Application                Administration route     References
  -------------------------------- ---------------------------------------------------------------- -------------------------- ------------------------ ------------
  Pentamidine                      Chitosan coated niosomes                                         Parkinson's disease        Intranasal               [@B120]
  Methotrexate                     Chitosan hydrogel nanoparticles                                  Antineoplastic agent       Intravenous              [@B110]
  Carbamazepine                    Chitosan coated lipid nanoparticle formulation                   Epilepsy                   Oral                     [@B4]
  Rotigotine                       Chitosan nanoparticles                                           Parkinson's disease        Intranasal               [@B150]
  Doxorubicin/erlotinib            Chitosan liposomal nanoparticles                                 Glioblastoma               --                       [@B72]
  Docetaxel                        TMC hydrogel                                                     Glioblastoma               Intracranial injection   [@B148]
  Risperidone                      Chitosan lipid nanoparticle                                      Schizophrenia              Intranasal               [@B111]
  Pramipexole dihydrochloride      Chitosan nanoparticles                                           Parkinson's Disease        Intranasal               [@B112]
  Galantamine                      Chitosan nanoparticles                                           Amnesia/Alzheimer          Intranasal               [@B142]
  Selegiline                       Chitosan nanoparticles                                           Parkinson Disease          Intranasal               [@B138]
  Temozolomide                     Nano lipid chitosan hydrogel                                     Antineoplastic agent       Intranasal               [@B63]
  Cyclovirobuxine d                Chitosan nanoparticles                                           Cerebrovascular disease    Intranasal               [@B161]
  Diazepam                         Chitosan mucoadhesive microemulsion                              Status epilepticus         Intranasal               [@B113]
  Tapentadol hydrochloride         Chitosan nanoparticles                                           Pain                       Intranasal               [@B58]
  Rivastigmine hydrogen tartrate   Chitosan mucoadhesive microemulsion                              Cholinesterase inhibitor   Intranasal               [@B129]
  Ribavirin                        Chitosan microparticle agglomerates                              Viral infection            Intranasal               [@B44]
  Huperzine A                      Lactoferrin-conjugated TMC surface-modified PLGA nanoparticles   Alzheimer's disease        Intranasal               [@B88]
  Ropinirolle-detran sulfate       Chitosan mucoadhesive neuro-nanoemulsion                         Parkinson's disease        Intranasal               [@B103]
  Zolmitriptan                     Chitosan mucoadhesive nanoemulsion                               Migraine                   Intranasal               [@B2]
  Desvenlafaxine                   PLGA-chitosan nanoparticles                                      Depression                 Intranasal               [@B146]
  Selegiline hydrochloride         Thiolated chitosan nanoparticles                                 Depression                 Intranasal               [@B133]
  Quetiapine fumarate              Chitosan microemulsion                                           Schizophrenia              Intranasal               [@B128]
  Rasagiline                       Chitosan glutamate nanoparticles                                 Parkinson's disease        Intranasal               [@B89]
  Ropinirole hydrochloride         Chitosan mucoadhesive nanoparticles                              Parkinson's disease        Intranasal               [@B56]
  Buspirone hydrochloride          Thiolated chitosan nanoparticles                                 General anxiety disorder   Intranasal               [@B9]
  Doxepin hydrochloride            Chitosan-glycerophosphate-PEG thermoreversible biogels           Depression                 Intranasal               [@B97]
  Buspirone                        Chitosan mucoadhesive microemulsion                              General anxiety disorder   Intranasal               [@B17]
  Donepezil                        Chitosan nanosuspension                                          Alzheimer disease          Intranasal               [@B11]
  Levodopa                         Chitosan nanoparticles                                           Parkinson's Disease        Intranasal               [@B132]

Gene Therapy {#S4.SS2}
------------

Gene therapy has been set as a form of drug delivery, where cellular machinery is modulated to produce a therapeutic effect ([@B13]). As in drug delivery systems, some of the most remarkable difficulties to direct this technology toward the CNS consist of low BBB permeability, brain heterogeneity, invasive or inefficient routes of administration, and dosing ([@B61]). Different types of vectors have been used to overcome these limitations, being the viral ones the most employed ([@B24]). Nevertheless, human infections and immune response caused by viral vectors have led to the search for safer vectors. The aforementioned polycationic property of chitosan confers the polymer the capacity to establish strong electrostatic interactions with negatively charged molecules, like DNA and RNA.

To this day many chitosan-based systems for gene delivery have been employed. [@B86] reviewed the formulation factors that affect siRNA and DNA delivery and transfection efficiency. They highlighted that the transfection efficiency depends on many parameters and concluded that intermediate values of Mw and DD of chitosan form complexes of intermediate stability and efficient transfection. Chitosan derivatives have also been employed for this purpose. Specifically, for therapeutic gene delivery to the brain, PEGylation has shown to enhance biocompatibility and stability of siRNA loaded complexes ([@B42]). Moreover, PEG plays the role of a linker between chitosan and targeting peptides, which form complexes with nucleic acid and enhance the cellular uptake of chitosan nanoparticles ([@B84]; [@B60]).

Despite the versatility of chitosan, nanoparticles have been the preferred candidates to counter different neurological disorders. Among these disorders are glioblastoma ([@B85]; [@B26]; [@B164]; [@B154], [@B153]), medulloblastoma ([@B64]), Parkinson's disease ([@B108]), Alzheimer's disease ([@B42]; [@B117]), and multiple sclerosis ([@B172]). Even viral infections, like HIV-infected brain, have been a target for this therapeutic strategy ([@B46]). Recently, the search for less invasive strategies has guided the development of novel formulations for nose-to-brain gene delivery. For example, [@B117], made chitosan-coated solid lipid nanoparticles carrying BACE1 siRNA for intranasal application against Alzheimer's disease. Similarly, [@B153] formulated siRNA targeting Gal-1 loaded chitosan nanoparticles for intranasal delivery in mice, obtaining remarkable changes in the tumor micro-environment of glioblastoma multiforme. Moreover, Sánchez-Ramos and his collaborators designed a chitosan-Mangafodipir intranasal nanocarrier system for the delivery of siRNA or dsDNA. They employed anti-eGFP siRNA and reported the effectiveness of the nanoparticles for reducing GFP mRNA expression in Tg GFP+ mice along different brain zones ([@B124]). These advances suggest an imminent overcoming of the difficulties that limit the CNS-directed gene therapy.

Chitosan-Based Materials for Tissue Engineering and Regenerative Medicine in CNS {#S5}
================================================================================

The design of different chitosan-based biomaterials for tissue engineering and regenerative medicine in CNS aims to facilitate neural cell adhesion, proliferation, and differentiation. These biomaterials can be used as scaffolds to mimic the natural extracellular matrix and microenvironment for better *in vitro* approaches or tissue replacement. Thus, these polymeric materials can be useful to overcome the limitations of cell therapy. For *in vitro* applications, the conformation of the biomaterials must present good biocompatibility and porous structures that favor 3D cell growth. Regenerative medicine requires biomaterials that offer mechanical support for growing neurites. Biological support is also required to lead the processes to tissue restoration through stem cell differentiation and integration into the surrounding healthy tissue ([@B16]). Moreover, it is important to cause a minimal inflammatory response when implanted. In this way, properties as biocompatibility, biodegradability, mechanical strength, architecture, and cell-adhesion capacity become crucial for biomaterial success.

[@B45] made a review article detailing the characteristics of chitosan-based scaffolds for nervous system regeneration. They highlighted that the physicochemical properties of chitosan (and modified chitosan) can be easily manipulated to design specific structural features for the scaffolds. According to the required structure and properties for tissue restoration, the biomaterial scaffolds for CNS regeneration can be classified into two types: hydrogels and biodegradable scaffolds ([@B159]). Chitosan hydrogels can be obtained by physical or chemical crosslinking. The physical associations, like ionic bonding and hydrogen bonds, provide unstable structures while the chemical associations formed by covalent bonds give place to uniform properties. For faster hydrogel biodegradation, it is recommended the use of labile bonds that can be broken under physiological conditions ([@B107]). On the other hand, *in situ* gelling can be achieved by physical interactions, providing the advantages of cell delivery without previous geometrical shape preparation of hydrogels and with a less invasive implantation process ([@B131]). For application in the CNS, hydrogels have been obtained from chitosan ([@B20]), its derivatives as CMC ([@B163]) and chitosan lactate ([@B98]), and mixtures with other polymers like gelatin ([@B41]). Biodegradable scaffolds are mainly structured by freeze-drying but can be also obtained by electrospinning, solvent evaporation, supercritical carbon dioxide, and 3D printing ([@B25]; [@B159]; [@B141]). For porous scaffolds, many chitosan-blends have been made by combining different biodegradable materials, like gelatin ([@B158]), collagen ([@B166]), and PEDOT ([@B157]), among others. One of the principal advantages of these scaffolds resides in having stabilized porous structures that can be designed with different size ranges and mechanical properties ([@B165]).

For non-CNS tissue engineering applications, Mw and DD have been associated with biodegradability and viscosity. Higher Mw gives delayed biodegradation when implanted, and more viscous biomaterials. DD values between 65 and 82% give faster biodegradation ([@B121]). It is worth mentioning that there is huge variability in the main chemical properties of the starting chitosans used in the reviewed studies, including Mw from 1 ([@B169]) to 550 kDa ([@B20]) and values of 75--95% of DD ([@B38]; [@B147]). Moreover, none of the reviewed CNS application studies in tissue engineering and regenerative medicine evaluates different Mw or DD in their starting materials. Many of the studies do not detail these two important chemical characteristics of their starting chitosan. Otherwise, the main variation in these works consists of using different polymeric blends and ratios as starting materials.

Implanting chitosan-based biomaterials in the CNS provides a way to its poor regenerative capacity through the reconstruction of lost tissue and reconnection of neuronal processes. Although, the incorporation of stem cells and biomolecules into these scaffolds has emerged as an additional strategy to enhance regenerative therapies ([@B119]). In this way, biomaterials assist cell therapy as delivery vehicles that promote cell survival and engraftment. Another advantage of the combination of both research areas is that the implanted cells can be separated from the host damaged tissue. Thereby, biomaterials provide an independent microenvironment for cell differentiation and proliferation, which does not occur in the natural response to damage ([@B159]).

Beyond the aforementioned physicochemical properties of chitosan that make it a suitable biopolymer to make biodegradable scaffolds and hydrogels, chitosan has neuroprotective properties. Anti-neuroinflammatory activity, suppression of β-amyloid and acetylcholinesterase formation, and anti-apoptosis effects have been reported ([@B102]; [@B50]). These neuroprotective effects promote an adequate microenvironment for cell proliferation in some CNS damage processes.

Chitosan-Based Scaffolding {#S5.SS1}
--------------------------

Over the past few years, many strategies for increasing cell adhesion, differentiation and viability on chitosan-based scaffolds have been implemented ([Table 2](#T2){ref-type="table"}). Different mixtures of biopolymers with chitosan have been employed for modulating the micro-structure of the scaffolds and their properties. For example, collagen copolymerization has proven to promote cell affinity through its arginine-glycine-aspartic acid sequence which is recognized by transmembrane integrins ([@B71]). In the same way, polylactic acid copolymerization gives rise to materials with better mechanical properties and it has been cataloged as a perfect synthetic polymer to elaborate composite materials with chitosan ([@B33]; [@B54]). On the other hand, [@B1] recently developed bionanocomposites of polyaniline-chloride/chitosan and observed that physical factors of the scaffolds (as electrical conductivity and morphology) have a bigger influence in cell-substrate interactions than molecular affinity. Also, [@B143] studied the behavior of Neuro-2a cells over flat, micro-, and nano-textured chitosan substrates, and found that cellular adhesion increases over flat chitosan surfaces. Given that the design of the internal structure and surface of the scaffolds is determinant for cell adhesion and proliferation, Sun and collaborators printed a collagen-chitosan 3D scaffold with a specific structure. They observed nerve fibers regeneration and functional recovery after its implantation in rats with spinal cord injury (SCI), showing enhanced therapeutic effects compared with the non-3D-printed material ([@B141]).

###### 

Chitosan-based biomaterials for implantation in CNS or neural cell culture reported in the last 5 years.

  Composition                                                                               Presentation                              Application                                                                            Model        References
  ----------------------------------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------- ------------ ------------
  Collagen and chitosan                                                                     3D printed scaffolds                      Implantation as therapeutic in SCI                                                     Rat          [@B141]
  Chitosan-multiwalled carbon nanotubes                                                     Nanomaterial scaffold                     Culture for implantation                                                               *In vitro*   [@B48]
  Polyaniline-chloride, chitosan, and NGF                                                   Microporous scaffolds                     Tissue engineering                                                                     *In vitro*   [@B1]
  Gelatin and glycine-functionalized polypyrrole-coated poly(vinyl alcohol) with chitosan   Scaffold                                  Culture for implantation                                                               Mice         [@B95]
  PEDOT, chitosan and gelatin                                                               Scaffold                                  Substrate for NSC research and neural tissue engineering                               *In vitro*   [@B157]
  Chitosan and PDGF                                                                         Scaffold and microspheres                 Tissue-engineered spinal cord grafts                                                   *In vitro*   [@B21]
  Chitosan                                                                                  Scaffold                                  Implantation in SCI                                                                    Rat          [@B169]
  NT-3 -- chitosan                                                                          Tube                                      Implantation in SCI                                                                    Monkey       [@B115]
  PEDOT and CMC                                                                             Conductive polymer layer/Hydrogel         Neural tissue engineering                                                              *In vitro*   [@B163]
  Chitosan and heparin                                                                      Scaffold                                  Culture of stem cells for implantation                                                 *In vitro*   [@B91]
  NT-3 -- chitosan                                                                          Chitosan particles                        Implantation in TBI                                                                    Rat          [@B51]
  Chitosan                                                                                  Fragmented physical hydrogel suspensión   Implantation in SCI                                                                    Rat          [@B20]
  Chitosan lactate                                                                          Hydrogel                                  Implantation in SCI                                                                    Rat          [@B98]
  Polyacrylamide, chitosan scaffold, and PLGA nanoparticles                                 Inverted colloidal crystal scaffold       Culture for iPS differentiation into neurons and implantation for nerve regeneration   *In vitro*   [@B68]
  Alginate, CMC, and agarose                                                                Porous 3D scaffold                        Tissue engineering                                                                     *In vitro*   [@B47]
  Chitosan and polylactic acid                                                              Nanofibrous scaffold                      Culture of stem cells for tissue engineering and cell-based therapy                    *In vitro*   [@B33]
  NT-3 -- chitosan                                                                          Tube                                      Implantation in SCI                                                                    Rat          [@B32]
  Chitosan                                                                                  Scaffold                                  Culture of stem cells for differentiation and implantation in TBI                      *In vitro*   [@B38]

The addition of neurotrophic factors into chitosan scaffolds or microspheres, like nerve growth factor (NGF), neurotrophin-3 (NT-3), or fibroblast growth factor-2 (FGF-2), has shown to enhance neurogenesis, neural differentiation, and cell survival ([@B170]; [@B135]; [@B32]; [@B51]). [@B115] elaborated NT-3 -- chitosan tubes that promoted neuroprotection, neurogenesis, revascularization, and antiinflammation on SCI conditions. After implantation, they observed robust neural regeneration with motor and sensory functional recovery in rhesus monkeys ([@B115]).

The implantation of chitosan hydrogels constitutes an interesting possibility for CNS restoration. Chitosan hydrogels have proved to provide a suitable micro-environment for axons regrowth and increase the survival rate of damaged neurons in different animal models. These hydrogels have shown remarkable potential in CNS repair, even in the absence of added trophic factors or without a detailed design of its structure ([@B147]; [@B98]). [@B20] elaborated a fragmented physical hydrogel suspension employing unmodified chitosan for its implantation in rat SCI (immediately after the injury). They observed axonal regrowth, modulated inflammatory response, and long-lasting locomotor function recovery ([@B20]). Even though more studies employing chitosan hydrogels are required to define their therapeutic potential in different damage models or degenerative diseases, these results provide a tool for future evaluations in combined repair strategies.

Chitosan-Based Materials and Cell Therapy to the CNS {#S5.SS2}
----------------------------------------------------

Spinal cord and brain injury, as well as neurodegenerative diseases, are conducted by different biological processes and cause diverse symptoms, though all of them result in neuronal degeneration and cell death. Cell therapies for CNS have attained clinical research in different pathological conditions like stroke, TBI, amyotrophic lateral sclerosis, and Parkinson's disease, showing their contribution to mitigating damage ([@B160]). However, within damage processes occur extracellular matrix, neuronal, and glial cell loss. This tissue loss results in a hostile environment for transplanted cells and causes deficient engraftment with poor cell viability ([@B14]). In recent years, the incorporation of different biomaterials to cell therapy in CNS has shown to promote cell survival, integration, and differentiation ([@B39]). In this way, chitosan-based biomaterials have been employed in combination with stem/precursor cells to build a way to neuro-regeneration ([Table 3](#T3){ref-type="table"}). The function of these biopolymeric structures is not only to serve as delivery vehicles and cell physical supports, besides they must regulate the biological microenvironment to guide axonal growth and favor the integration of the healthy tissue to the lesion zone ([@B16]). Some of the most studied cells for CNS repair are the mesenchymal stem cells (MSC), bone marrow mesenchymal stem cells (BM-MSC), neural stem cells (NSC), and neural precursor cells (NPC).

###### 

Chitosan-based biomaterials for CNS cell therapy reported in the last 5 years.

  Composition                                                                                       Cells                           Presentation            Application                                                     Model              References
  ------------------------------------------------------------------------------------------------- ------------------------------- ----------------------- --------------------------------------------------------------- ------------------ ------------
  Collagen and chitosan                                                                             BM-MSC                          Porous scaffold         Implantation in TBI                                             Rat                [@B166]
  Polyaniline-chloride, chitosan, and NGF                                                           PC12/NIH/3T3                    Microporous scaffold    Neural tissue engineering                                       *In vitro*         [@B1]
  Chitosan, genipin, heparin, FGF-2, and fibronectin                                                NPC/genetically modified NPC    Microspheres            Implantation as therapeutic in TBI                              Rat                [@B136]
  Poly(ε-caprolactone), chitosan, and polypyrrole                                                   PC12                            Nanofibrous scaffold    Neural tissue substitute                                        *In vitro*         [@B123]
  Chitosan                                                                                          BM-MSC                          Porous scaffold         Implantation in TBI                                             Rat                [@B144]
  Methacrylamide chitosan, dibenzocyclooctyne-acrylic acid, and laminin azide-tagged interferon γ   NSC                             Conduit                 Implantation in SCI                                             Rat                [@B37]
  PEDOT, gelatin, and chitosan                                                                      NSC                             Scaffold                Neural tissue engineering                                       *In vitro*         [@B158]
  Chitosan                                                                                          NSC and MSC                     Co-spheroids            Implantation in TBI                                             Zebrafish          [@B49]
  Chitosan                                                                                          MSC from dental pulp            Scaffold                Implantation in SCI                                             *In vitro*         [@B176]
  Chitosan                                                                                          MSC                             Scaffold                Implantation in SCI                                             Rat                [@B66]
  Chitosan, genipin, heparin, fibronectin, and FGF-2                                                Retinal ganglion cells          Microspheres            Cellular and growth factor delivery vehicle in TBI              Rat                [@B134]
  Chitosan and gelatin                                                                              BM-MSC                          Scaffold                Implantation in spina bifida                                    Rat fetuses        [@B76]
  Chitosan and collagen                                                                             BM-MSC                          Scaffold                Implantation in ischemic stroke                                 Rat                [@B167]
  Chitosan, polylactic acid, NGF, and bGFG                                                          PC12                            Scaffold                Neural cell differentiation for transplantation in a MS model   Mice               [@B54]
  Glycol chitosan and DF-PEG                                                                        NSC                             Self-healing hydrogel   Implantation in neural injury                                   Zebrafish embryo   [@B147]
  Methacrylamide chitosan, collagen, IFN-y, and acrylated laminin                                   NSC                             Conduit                 Implantation in SCI                                             Rat                [@B74]
  Chitosan and gelatin                                                                              MSC from human adipose tissue   Scaffold                Implantation in TBI                                             Mice               [@B41]

A study reported by [@B140] showed that modified-chitosan microfibers promote neural stem/progenitor cell proliferation *in vitro* but not cell survival after transplantation, contrary to collagen-based microfibers. The authors proposed that the stiffness of chitosan precluded the colonization of other cells, like vascular epithelial cells ([@B140]). The stiffness of the scaffolds should be in the range of 0.1--1 kPa for mimicking soft tissue like the brain. It is well known that stiffness has a notorious influence on stem cell response and function ([@B78]). Moreover, it has been proved that cell size affects the cellular response to matrix stiffness in 3D cultures, especially large cells as many of the human stem cells ([@B8]). So, in these cell-scaffold strategies, it is very important to consider the starting material and cell population. The main advantage of using chitosan as the starting material for this purpose is its high versatility. Thus, stiffness and other important characteristics that affect cell behavior, as viscoelasticity, porosity, and topography can be easily modulated.

Besides its versatility, chitosan and its derivatives have shown to be a superior substrate for cell therapy in comparison with other polymers. [@B126] showed the capability of adult murine NPC to proliferate and differentiate into the three neural cell types when they were cultured over chitosan hydrogel films. On the contrary, NPC differentiation was not observed over poly(oligoethylene oxide dimethacrylate-*co*-2-amino ethyl methacrylate) or its blend with poly(vinyl alcohol), neither over poly(glycerol dimethacrylate-*co*-2-amino ethyl methacrylate) ([@B126]). [@B66] observed a better functional improvement in rats with SCI after MSC transplantation over chitosan scaffolds in contrast to PLGA scaffolds. Moreover, they studied intralesional injection of the same cells and compared it with scaffold-based transplantation in rats. They found a higher MSC engraftment when the scaffolds were employed ([@B66]). The culture of rat PC12 line and human neural stem cells over chitosan has also shown better results in comparison with cellulose acetate or polyethersulfone derived electrospun nanofibers ([@B31]).

The incorporation of trophic factors as FGF-2, NGF, PDGF, and bGFG has also shown to enhance stemness of neural stem cells and favor its differentiation and proliferation when implanted with chitosan scaffolds or microspheres ([@B54]; [@B134]; [@B91]). Recently, Skop and his collaborators designed a cell-scaffold strategy employing a radial glial neural precursor cell line that conditionally secreted insulin-like growth factor I. This cell line was attached to a chitosan-based microsphere scaffold and injected into the lesion cavity of adult rats with TBI. They observed differentiation toward the three neural cell types (neurons, astrocytes, and oligodendrocytes) and improved capacity for neuronal differentiation. These obtained effects led to the recovery of the somatosensory function. However, the presence of insulin-like growth factor I was not associated with a higher cell retention rate or improved cell replacement. So, the way it improves functional recovery must be elucidated in future studies ([@B136]).

Conclusion {#S6}
==========

One of the main factors that preclude the application of chitosan is its poor solubility and poor mechanical properties. However, this review summarizes the different strategies that have been used to overcome these conditions. The obtention of carboxymethylated, trimethylated, thiolated and other chitosan-grafted derivatives has increased the potential of this biopolymer, allowing for the elaboration of biomaterials that help to counteract neurological disorders. Nevertheless, there is still a lack of knowledge about the relation of the molecular changes and the acquired biological properties of these derivatives, especially within a heterogeneous landscape as the CNS. In this way, the authors suggest continuing with the exploration of grafting molecules that improve the biological properties of modified chitosan. For example, hydroxycinnamic acids have been studied by some of the authors and resulted in interesting bioconjugates for CNS applications.

Chitosan-based biomaterials have shown favorable projection. For drug and gene delivery purposes, chitosan nanoparticles have shown to be the most promising strategy due to its mucoadhesion and increased permeability that suits nose-to-brain applications. In this way, the degradation of the therapeutic molecules is reduced, and it also opens the door to less invasive and more effective administration routes. In order to achieve neuro-regeneration, the transplant of stem cells into chitosan-based vehicles gives an optimistic outlook. Strategies like the addition of neurotrophic factors or even the genetic modification of stem cells have successfully increased differentiation and viability. The observed functional recovery in different chitosan-based regenerative therapies encourages the exploration of new cell-scaffold-biomolecule configurations. Despite the wide variety of designed compositions and functions, many factors are implied in cell behavior and, until now, there is not a recipe to elaborate adequate chitosan-based biomaterials that fulfill all the requirements for neuro-repair and to transfer these strategies to clinical trials. Even so, the *in vitro* and *in vivo* studies carried out around the world are helping to understand the biological processes involved in neuro-repair and the effect of chitosan biomaterials on them. The authors suggest that future works with chitosan targeting the CNS must intermix the already suggested strategies and propose novel interdisciplinary approaches to attain translation into the clinical level.
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